Ralph P. George Jr., M.D.; James L. Poth, M.D.; David Gordon, M.D.; Stanley L. Schrier, M.D.
This content is PDF only. Please click on the PDF icon to access.
Controversy exists regarding the efficacy of various treatment schedules and drug combinations for patients with multiple myeloma. This study compared results of long-term, continuous alkylator therapy with those of intermittent, high-dose pulse therapy using melphalan and prednisone in combination. During the past 2 years 31 patients with multiple myeloma were treated with high-dose, combination pulse therapy using melphalan, 0.25 mg/kg body weight/day, and prednisone, 2.0 mg/kg body weight/day. Both drugs were given orally for 4 days at 6-week intervals. The results were compared with previous experience at the Stanford University Hospital using continuous, low-dose alkylator therapy in 22 patients with
George RP, Poth JL, Gordon D, et al. Multiple Myeloma—Intermittent, Combination Chemotherapy Compared with Low-Dose Continuous Alkylator Therapy.. Ann Intern Med. 1971;74:836–837. doi: 10.7326/0003-4819-74-5-836_5
Download citation file:
Published: Ann Intern Med. 1971;74(5):836-837.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use